Pathological roles of MRP14 in anemia and splenomegaly during experimental visceral leishmaniasis

Kanna Ishizuka¹, Wataru Fujii², Natsuho Azuma¹, Haruka Mizobuchi¹, Ayako Morimoto¹, Chizu Sanjoba¹, Yoshitsugu Matsumoto¹, Yasuyuki Goto*¹

¹ Laboratory of Molecular Immunology, Department of Animal Resource Sciences, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan, ² Laboratory of Applied Genetics, Department of Animal Resource Sciences, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan

* aygoto@mail.ecc.u-tokyo.ac.jp

Abstract

Myeloid-related protein 14 (MRP14) belongs to the S100 calcium-binding protein family and is expressed in neutrophils and inflammatory macrophages. Increase in the number of MRP14+ cells or serum level of MRP14 is associated with various diseases such as autoimmune diseases and infectious diseases, suggesting the involvement of the molecule in pathogenesis of those diseases. In this study, to examine the pathological involvement of MRP14 during cutaneous and visceral leishmaniasis, wild-type (WT) and MRP14 knockout (MRP14KO) mice were infected with Leishmania major and L. donovani. Increase in the number of MRP14+ cells at the infection sites in wild-type mice was commonly found in the skin during L. major infection as well as the spleen and liver during L. donovani infection. In contrast, the influence of MRP14 to the pathology seemed different between the two infections. MRP14 depletion exacerbated the lesion development and ulcer formation in L. major infection. On the other hand, the depletion improved anemia and splenomegaly but not hepatomegaly at 24 weeks of L. donovani infection. These results suggest that, distinct from its protective role in CL, MRP14 is involved in exacerbation of some symptoms during VL.

Author summary

Inflammatory responses are crucial in limiting pathogen infections, whereas they often have detrimental effects to the hosts during infectious diseases. Thus, exploring molecules involved in inflammatory responses and targeting those molecules may contribute to development of novel interventions for symptom management during infectious diseases. Although an inflammation-related protein, MRP14, is associated with a wide range of inflammatory diseases, the functions remain elusive. Therefore, we explored the roles of MRP14 in a protozoan disease called leishmaniasis because its pathology is known to be immune-mediated. Interestingly, in two distinct forms of leishmaniasis, i.e., cutaneous
leishmaniasis caused by *Leishmania major* and visceral leishmaniasis caused by *L. donovani*, the molecule showed distinct roles in protection/pathology; although the molecule was protective against *L. major* infection, depletion of the molecule resulted in easing the pathology during *L. donovani* infection. These may prove the complexity of MRP14, but at the same time support understanding of the mechanisms behind the complexity.

**Introduction**

Myeloid-related protein (MRP) 14, also known as S100A9, belongs to the S100 calcium-binding protein family and can form the heterodimer with MRP8, which is known as S100A8 [1,2]. S100 protein family proteins contain two Ca$^{2+}$-binding regions known as EF-hands and play a role in cell differentiation, cell cycle progression, regulation of kinase activity, and cytoskeletal-membrane interactions when Ca$^{2+}$ bind [3]. The expression of MRP14 and MRP8 is specific for myeloid cells such as granulocytes, monocytes and macrophages in inflamed tissue [4]. They are abundant cytoplasmic proteins of neutrophils and monocytes [1,5], and also known as markers of inflammatory macrophages. MRP14 expression is abundant in immature monocytes and is lost as the cells terminally differentiate into tissue macrophages, so MRP14 can be associated with monocytic differentiation [6].

MRP14 has been characterized as an inflammation-related protein [7–9]. Extracellular MRP14 and MRP8 are known to function as damage-associated molecular patterns (DAMP), which are endogenous molecules or alarmins released after cell activation or necrotic cells and are secreted by the inflammatory cells when activated [10]. Neither MRP14 nor MRP8 has a signal sequence for secretion via classical ER/Golgi route, but it is demonstrated that these proteins are secreted after activation of protein kinase C via tubulin-dependent pathway [10]. Extracellular MRP14 and MRP8 bind Toll-like receptor (TLR) 2, TLR4 and receptor for advanced glycation endproducts (RAGE) and induce cell recruitment and cell activation [11–14]. It is also reported that MRP14 promotes inflammatory process in infection and autoimmunity via TLR4 [9,12,15], and cell growth in cancer and cell migration via RAGE [16,17]. Actually, MRP8 and MRP14 in serum are elevated in various diseases [18–20]. In inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, and coronary syndromes, the accumulation of cells expressing MRP14 or MRP8 is observed at inflammatory sites [18,21–23]. Therefore, it is considered that MRP14 plays a critical role in the pathogenesis in these diseases. In malaria, we reported that macrophages expressing MRP14 accumulated in the spleen and liver of BALB/c mice and MRP14 level in the plasma was also elevated during *Plasmodium berghei* ANKA infection [24]. In addition, the administration of recombinant MRP14 exacerbated hepatic injury and promoted the up-regulation of pro-inflammatory molecules in the liver [11]. These reports suggest MRP14 is one of the key molecules for pathogenesis of malaria. In the present study, pathological involvement of MRP14 in leishmaniasis, which is caused by parasite infection as well as malaria, was examined.

The leishmaniasis is caused by protozoan parasites of the genus *Leishmania*. Human leishmaniasis is typically classified into three types, cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis and visceral leishmaniasis (VL). *Leishmania major* is one of the causative agents for CL, which is characterized by clinical manifestations such as ulcers on the skin and permanent scars after the ulcers heal. VL, also known as kala-azar, is caused by infection of *Leishmania* species including *L. donovani* and *L. infantum* [25,26] and is characterized by clinical manifestations such as fever, substantial weight loss, hepatosplenomegaly, and anemia. During CL and VL, macrophages are the host cells of *Leishmania* parasites in the mammalian hosts,
and the parasites proliferate within macrophages in the skin lesion and lymph node during CL and in the spleen, liver, and bone marrow during VL.

During experimental CL, MRP14+ cells are predominant cells accumulated in the skin lesion during L. major infection in BALB/c mice [27]. A study using MRP14 knockout (MRP14KO) C57BL/6 mice showed a protective role of MRP14 in L. major infection to footpad [28]. Such the protective role has been confirmed also in BALB/c mice as injection of recombinant MRP14 into the lesion induced reduction in parasite burden and suppression of lesion development [28]. In contrast, the role of MRP14 in L. donovani infection has not been studied yet. Because the symptoms are very different between CL and VL, the role of MRP14 in pathology of VL may be different from that in CL. Therefore, by utilizing MRP14KO BALB/c mice, we addressed the influence of MRP14 on pathology during L. donovani infection and compared with L. major infection. The results revealed that the molecule can exacerbate splenomegaly and anemia during L. donovani infection whereas it can contribute to control of L. major infection. By comparing the influence of MRP14 during L. major and L. donovani infection, it was revealed that how MRP14 involves in pathogenesis is variable.

Materials and methods

Animals

BALB/cA mice were purchased from Japan Clea, Tokyo, Japan, and were maintained under specific pathogen-free conditions. MRP14KO BALB/cA mice were generated by offset-nicking method of CRISPR/Cas system according to previous report [29,30]. Mice were bred in the animal facility at the Graduate School of Agricultural and Life Sciences, The University of Tokyo. The mice were used for experiments at the age of 6–9 weeks. The animal experiments were reviewed and approved by an institutional animal research committee (Approval No. P16-285) and an institutional committee on genetically modified organisms (Approval No. 830–2630) at the Graduate School of Agricultural and Life Sciences, The University of Tokyo. Animal health and well-being was assessed in accordance with the Guidelines for Proper Conduct of Animal Experiments (the Science Council of Japan) and the National Institutes of Health guidelines for the use of experimental animals.

Parasites

L. major promastigotes (MHOM/IL/80/Friedlin; provided by Dr. Steven Reed, Infectious Diseases Research Institute) were cultured in medium TC199 supplemented with 20% HI-FBS and 25 mM HEPE5 buffer at 25°C. L. donovani promastigotes (MHOM/NP/03/D10; a gift from the National BioResource Project at Nagasaki University [31]) were cultured in medium TC199 (Nissui Pharmaceutical, Tokyo, Japan) supplemented with 10% heat-inactivated fetal bovine serum (HI-FBS; Thermo Scientific, Waltham, USA) and 25 mM HEPE5 buffer (MP Biomedicals, France) at 25°C.

Animal infection

Preparation of metacyclic promastigotes was performed using peanut agglutinin as previously described [32]. Mice were infected with 1 × 10^4 L. major metacyclic promastigotes by intradermal injection into the left ear [33]. The longer axis of the lesion and that of the ulcer were measured with a digital caliper every week [34]. These mice were sacrificed at 10 weeks after infection or earlier if severe damage to the auricle was evident. The number of parasites in lymph nodes at sacrifice was determined by limiting dilutions [35]. The tissues were homogenized using glass homogenizer in 1 ml of TC199 medium containing 20% HI-FBS, 25 mM
HEPES buffer, penicillin (100 U/ml) and streptomycin (100 μg/ml) (Invitrogen, CA, US). Two-fold serial dilutions of the homogenates were made in 96 well plates up to 1:2^23. After 14 days of incubation at 25˚C, the plates were examined for the presence of promastigotes. The parasite number in each sample was calculated by defining the last positive well as containing one amastigote at the beginning. Two independent L. major infections were performed.

*L. donovani* promastigotes in stationary phase were washed with phosphate-buffered saline (PBS: Nissui Pharm) by centrifugation at 1,600 ×g for 10 min and were resuspended with PBS at the concentration of 1 × 10^8 cells/ml. Mice were infected with 1 × 10^7 *L. donovani* promastigotes by intravenous injection into the tail vein. Twenty-four weeks after infection, the mice were sacrificed by cervical dislocation to collect the spleen and liver. Stamp smears of the spleen and liver were fixed for 5 min in methanol and stained for 25 min with 5% Giemsa solution (Merck KGaA, Parmstadt, Germany). Amastigotes were counted by microscopic observation of the stained smear at 1,000× magnification, and Leishman-Donovan Units (LDU) were enumerated as the number of amastigotes per 1,000 host nuclei times the tissue weight in grams as performed in a previous study [36]. Three independent *L. donovani* infections were performed.

**Immunohistochemical analyses**

Immunohistochemical staining was performed as previously described [24]. Briefly, for immunohistochemical staining, paraffin-embedded tissues, sectioned at 4 μm thickness, were dewaxed and boiled in Tris-EDTA buffer (10 mM Tris Base, 1 mM EDTA-2Na, 0.05% Tween 20, pH 9.0) for 20 minutes. After blocking, anti-MRP8 and anti-MRP14 antibody (Santa Cruz Biotechnology, Texas, USA) was applied to the serial sections of tissues. After washing with PBS, sections were incubated with biotinylated anti-goat IgG (Nichirei Bioscience, Tokyo, Japan). Finally, enzymatic color development was performed by using 4-[(4-amino-m-tolyl) (4-imino-3-methylcyclohexa-2, 5-dien-1-ylidene) methyl]-o-toluidine monohydrochloride (new fuchsine, Nichirei Bioscience).

The number of MRP8^+ cells in the immunohistochemically stained spleen were counted in 10 random microscopic fields at 200× magnification. For the spleen, the cells in the red pulp were counted.

**HE staining**

The skins were collected from *L. major*-infected mice after 10 weeks of infection, and the tissues were fixed with 20% neutral buffered formalin and embedded in paraffin. The paraffin-embedded tissues were sectioned at 4 μm thickness. The tissues were stained with Mayer’s hematoxylin solution (WAKO, Osaka, Japan) for 1.5 min and rinsed in running tap water for 30 min. Next, the tissues were stained with eosin solution (MUTO PURE CHEMICALS CO., Ltd., Tokyo, Japan) for 2 min.

**Quantitative RT-PCR**

RNA from the spleens from *L. donovani*-infected mice was extracted using TRIzol (Thermo Fisher Scientific) and cDNA was synthesized by reverse transcription. The spleens were homogenized with 1 ml TRIzol and φ1.0 stainless steel beads in the 2 ml tube using Micro Smash MS100R (Tomy Seiko) at 4˚C and RNA was purified according to the manufacture’s protocol. The concentration of total RNA was measured by DU 730 Life Science UV/vis spectrophotometer (Beckman Coulter). A mixture of 1.25 μM oligo (dT)_16, 0.5mM dNTPs (Thermo Fisher Scientific) and 1 μg of total RNA in a tube was incubated for 5 min at 65˚C. After adding 5× first strand buffer and 10 mM DTT (Thermo Fisher Scientific), 200 U
M-MLV (Thermo Fisher Scientific) was added and the tube was incubated for 50 min at 37˚C and 15 min at 70˚C. Real-time PCR assay was carried out using 2 μl of cDNA as the template, 10 μl of SYBR Select Master Mix (Thermo Fisher Scientific) and primers listed in S1 Table [11,37] on the ABI Prism 7000 Sequence Detection System (Thermo Fisher Scientific). Data was analyzed by 2^−ΔΔCt methods and normalized by GAPDH. The thermal cycling conditions for the PCR were 94˚C for 10 min, followed by 40 cycles of 94˚C for 15 sec and 60˚C for 1 min.

T cell assay
To examine T cell reactivity, 2 × 10^5 cells per well of splenocytes from L. major- and L. donovani-infected WT and MRP14KO mice in RPMI-1640 medium (Sigma-Aldrich) supplemented with 10% HI-FBS, 100 U/ml of penicillin and 100 μg/ml of streptomycin were plated in a 96-well round-bottom plate (Thermo Fisher Scientific) and stimulated with 3 μg/ml of concanavalin A, 10 μg/ml of L. major- or L. donovani-derived soluble lysate antigen (LmA or LdSLA), or medium alone. Culture supernatants were collected after 72 hours cultivation in 5% CO₂ at 37˚C and tested the levels of interferon-γ (IFN-γ) by using Mouse IFN gamma ELISA Ready-SET-Go! Kit (eBioscience) according to manufacturer’s instruction.

Statistical analyses
Statistical analyses were performed using GraphPad Prism 6 software (GraphPad Software, Inc., La Jolla, USA). Mann-Whitney test was used to compare the differences in the results from two independent groups. The differences in MRP8⁺ cell accumulation between WT and MRP14KO mice were analyzed by two-way ANOVA followed by Sidak’s multiple comparisons test. A difference between groups was considered as statistically significant when the P value was less than 0.05.

Results
MRP8⁺ and MRP14⁺ cells at the infection sites in WT mice during L. major and L. donovani infection
Microscopic observation of the HE-stained ear of L. major infected BALB/c mice at 10 weeks post infection revealed that pathological changes compared with that of the naïve mice (Fig 1A). In L. major infection, cell accumulation was found between epidermal tissues in skin lesion. To characterize the accumulated cells, the expression of MRP8 and MRP14 was examined by immunohistochemistry (IHC). Few MRP8⁺ and MRP14⁺ cells were found in skin of naïve mice, while both MRP8⁺ cells and MRP14⁺ cells were accumulated in dermal tissues of skin lesion and were predominant cell types in the lesion (Fig 1B).

To examine if accumulation of MRP8⁺ and MRP14⁺ cells is also induced during VL, IHC of the spleen and liver from L. donovani infected BALB/c mice was performed. MRP8⁺ and MRP14⁺ cells were observed in the spleen of naïve mice and their numbers increased after 24 weeks of infection (Fig 1C). MRP8⁺ and MRP14⁺ cells were found only in the red pulp of both naïve and infected mice. Although few MRP8⁺ and MRP14⁺ cells were found in the liver of naïve mice, those cells increased during L. donovani infection as a part of granuloma formations (Fig 1D).

A major difference in MRP8⁺ and MRP14⁺ cells between L. major infection and L. donovani infection was the presence of parasites in those cells. In MRP8⁺ and MRP14⁺ cells accumulated in the skin lesion of L. major-infected mice, the nuclei of parasites were often found (Fig 1E). In contrast, signal of MRP8 or MRP14 was not observed in the parasitized macrophages (Fig 1F). Especially in the liver, it was typical that granuloma formations were composed of parasitized macrophages in the middle which were negative for MRP8 or MRP14,
whereas MRP8⁺ and MRP14⁺ cells were found in the surrounding area and were unparasitized (Fig 1F).

**Exacerbated lesion development in *L. major* infection and alleviated anemia and splenomegaly in *L. donovani* infection by MRP14 depletion**

In order to see the role of MRP14 in lesion development during *L. major* infection, ear lesion size and ulcer size of the infected WT and MRP14KO mice were measured every week. Although both WT and MRP14KO mice developed skin lesion and ulcer, MRP14 depletion significantly exacerbated lesion development and ulcer formation (Fig 2A). Mean length ± SD of the long diameter of the skin lesion in WT and MRP14KO mice at 10 weeks post infection were 6.4 ± 1.9 mm and 10.8 ± 2.5 mm, respectively. Mean length ± SD of the ulcer size were 2.7 ± 2.6 mm and 7.7 ± 3.6 mm, and the ulcers in MRP14KO mice were found 1 week earlier than WT mice. In contrast, mean parasite numbers in auricular lymph node were not significantly different between the infected WT and MRP14KO mice (Fig 2B).

Next, WT and MRP14KO mice were examined for major symptoms of VL, i.e., anemia, leukopenia and hepatosplenomegaly during *L. donovani* infection. Before infection, hematocrit, hemoglobin levels, and red blood cell counts in peripheral blood of WT mice (48.4 ± 0.9%, 15.5 ± 1.0 g/dl, 7.8 ± 1.0 × 10⁶ cells/μl) were comparable to those of MRP14KO mice (47.9 ± 1.3%, 15.2 ± 0.9 g/dl, 7.5 ± 1.4 × 10⁶ cells/μl). In contrast, WT mice developed anemia after 24 weeks of infection represented by lower hematocrit, hemoglobin levels and red blood cells count in peripheral blood (38.9 ± 2.0%, 10.1 ± 0.9 g/dl and 6.4 ± 0.3 × 10⁶ cells/μl, respectively), whereas MRP14KO mice did not exhibit anemia showing higher hematocrit, red blood cells count and hemoglobin in peripheral blood (46.0 ± 1.9%, 13.5 ± 1.6 g/dl and 8.9 ± 0.8 × 10⁶ cells/μl, respectively) than the infected WT mice (Fig 2C). Mean ± SD of white blood cells in the infected MRP14KO mice (5,200 ± 1,651 cells/μl) were significantly different from that of WT mice (2,525 ± 1,037 /μl) (Fig 2C). Splenomegaly in the infected MRP14KO mice was milder than that in the infected WT mice whereas hepatomegaly was similarly induced in both mice. Means ± SD of spleen weights per body weight in naïve WT and MRP14KO mice were 0.26 ± 0.04% and 0.25 ± 0.02%, and those from the infected WT and MRP14KO mice were 3.54 ± 0.54% and 2.71 ± 0.20%, respectively (Fig 2C). Means ± SD of liver weights per body weight in naïve WT and MRP14KO mice were 4.83 ± 0.24% and 5.82 ± 0.08%, and those from infected WT and MRP14KO mice were 7.21 ± 0.27% and 6.92 ± 0.23% (Fig 2C). Means ± SD of LDU in the spleen of the infected WT and MRP14KO were 4,128 ± 1,209 and 2,189 ± 271, respectively (Fig 2D). Those of liver were 2951 ± 381.2 and 1991 ± 1780 (Fig 2D). There was no significant difference in either spleen or liver parasite burdens between WT and MRP14KO mice.

**MRP14-dependent accumulation of MRP8⁺ cells during infection with *L. major* but not *L. donovani***

To investigate whether MRP14 depletion affects accumulation of MRP8⁺ cells, the density of MRP8⁺ cells were compared between WT and MRP14KO mice during *L. major* or *L. donovani* infection.
infection. In *L. major* infection, although accumulation of MRP8+ cells was induced in MRP14KO mice, the degree of the cell accumulation was lower in the KO mice compared with WT mice (Fig 3A). Accumulation of MRP8+ cells was also found in the spleen of *L. donovani*-infected MRP14KO mice (Fig 3B). In contrast to the case of skin lesion in *L. major* infection, the degree of the cell accumulation was comparable between WT and KO mice during *L. donovani* infection (Fig 3C).

Means ± SD of the number of MRP8+ cells in the red pulp of the spleen in naive and 24 week-infected WT mice were 628 ± 56 cells/mm² and 1,467 ± 145 cells/mm², and those in MRP14KO mice were 516 ± 106 cells/mm² and 1,400 ± 181 cells/mm² (Fig 3C).

No apparent influence of MRP14 depletion on antigen-specific T cell responses during *Leishmania* infection

To examine if the absence of MRP14 affects the induction of T cell responses during *Leishmania* infection, splenocytes were harvested from mice infected with *L. major* or *L. donovani* and stimulated in vitro with SLA for 3 days. IFN-γ secretion from splenocytes was induced by recall with SLA and there was no difference between WT and MRP14KO mice with *L. major* infection (Fig 4A). In contrast, antigen-specific T cell reactivity was minimal during *L.
The role of MRP14 in experimental visceral leishmaniasis
Donovani infection. Splenocytes from *L. donovani*-infected mice did not produce much IFN-γ level upon recall with SLA, and the responses were not significantly different between WT and MRP14KO mice (Fig 4B).

Up-regulated expression of NOSs and IFN-γ mRNA in the spleen of MRP14KO mice during *L. donovani* infection

Because anemia and splenomegaly were alleviated in MRP14KO mice than WT mice during *L. donovani*, inflammatory responses in the spleen of *L. donovani*-infected mice were analyzed by measuring mRNA levels of inflammation-associated proteins. Although the mRNA expression of MRP8 and MRP14 were up-regulated after 24-week infection in WT mice, the level of MRP8 was similarly up-regulated in infected MRP14KO mice (Fig 5). The expression level of tumor necrosis factor-α was unchanged at 24 weeks post infection in both WT and MRP14KO mice (Fig 5). In contrast, NOS2 and IFN-γ mRNA levels in WT mice at 24 weeks post infection were remarkably up-regulated than in naïve mice, while the levels in MRP14KO mice were significantly lower compared to WT mice (Fig 5).

Discussion

MRP14 is associated with inflammatory diseases [38]. In the present study, pathological roles of MRP14 in *L. major* and *L. donovani* infection were examined by using MRP14KO BALB/c mice we have previously generated [29]. Results in this study demonstrated different involvement of MRP14 in pathology during the two infections.

A previous study shows a protective role of MRP14 during *L. major* infection by using MRP14KO C57BL/6 mice [28]. Because the roles of MRP14 in inflammatory responses may differ in mice with different genetic backgrounds [29], we first evaluated the protective role of MRP14 in infection of BALB/c mice with *L. major*. In the ear infected with *L. major*, accumulation of MRP14+ cells and MRP8+ cells were induced (Fig 1), and the accumulation seemed to be dependent in part on endogenous MRP14 (Fig 3). It is reported that transfer of MRP8+ and MRP14+ cell induces further accumulation of MRP8+ and MRP14+ cells during *L. major* infection [39]. This report is in concordance with the presented result. MRP8/MRP14 are known to induce the production of proinflammatory chemokines by microvascular endothelial cells [40], accumulation of MRP8+ and MRP14+ cells to the infection site followed by secretion of those molecules may induce a positive feedback on the inflammatory response in *L. major* infection. MRP14 depletion exacerbated skin lesion development and ulcer formation in *L. major* infection without affecting the parasite burden (Fig 2). Contreras *et al.* demonstrated that injection of recombinant MRP14 into *L. major* infection site relieves lesion development and also reduces parasite burden, and treatment with anti-MRP8/14 does the opposite [28]. Actually, they also showed by in vitro experiments that MRP8 and MRP14 can activate macrophages to kill parasites with up-regulated TNF and iNOS [28]. In our study, parasites burdens in the lymph node were not statistically different between WT mice and MRP14KO mice with *L. major* infection. Therefore, it is possible that although MRP14 has a role in parasite clearance during *L. major* infection, control of lesion development by MRP14 is operated by other...
mechanisms. But how the loss of MRP14 or the resulting suppressed accumulation of MRP8\(^+\) cells affect the lesion worsening is still elusive and further studies are needed. We did not measure parasite burdens in the ear in this study because parasite burdens in the ear and the draining lymph node are generally proportional \[41\], but it is possible that MRP14 has a protective role not in lymph nodes but in the ear. This should be also addressed in future studies.

During *L. donovani* infection, accumulation of MRP14\(^+\) cells and MRP8\(^+\) cells was observed in both spleen and liver (Fig 1). Although the cell accumulation into the infection sites is common between CL and VL, contribution of MRP14 to MRP8\(^+\) cell accumulation was different between those models. The degree of MRP8\(^+\) cell accumulation to the spleen in MRP14KO mice was comparable that in WT mice either during *L. donovani* infection, whereas the cell accumulation was suppressed in the KO mice during *L. major* infection (Fig 3). These results suggest that MRP14 can act differently in inflammatory responses on distinct infections.

Intriguingly, MRP14 depletion resulted in improvement of anemia and splenomegaly but not for hepatomegaly (Fig 2).

So, how does MRP14 act differently on pathology of leishmaniasis? Control of skin lesion in CL and exacerbation of anemia in VL, which sound opposite, are both regulated by MRP14. One explanation can be variable roles of MRP8\(^-\) and MRP14\(^+\) cells as host cells for *Leishmania*.
parasites. It is reported that MRP14+ cells have different characteristics from F4/80+ cells in terms of infectivity and parasite clearance [39]. We previously reported that MRP8+ and MRP14+ cells rather than F4/80+ cells are the major subtype of macrophages in the skin lesion during L. major infection [27]. A similar result has been reported in L. amazonensis infection; CD11b+ cells but not F4/80+ cells are dominant infected cells in the infected footpad [42]. In contrast, infected macrophages in the spleen are F4/80+ during L. donovani infection (Fig 1).

If characters of the host macrophages are different between L. major and L. donovani infection, it is possible for MRP14 to act differently on parasite clearance and pathology during CL and VL. For example, such differences can be derived from different repertoires of MRP14 receptors on host macrophages. Multiple receptors including TLR2, TLR4 and RAGE are proposed as MRP14 receptors and the function of MRP14 varies depending on which receptor it binds. MRP14 induces inflammatory cytokine production via TLR4, while MRP14 induces leukocyte migration such as granulocytes, monocytes and lymphocytes via RAGE [15]. Besides, MRP14 induces accumulation of myeloid derived suppressor cells via RAGE [44]. Although outcomes of MRP14 signaling via TLR2 are still unknown, it is possible that each receptor has a different role and the expression pattern of the receptors at the infection sites changes the role of MRP14. Therefore, further characterizations on MRP14+ cells in terms of the receptor expressions are needed to understand the different outcomes of MRP14 depletion between CL and VL.

Or, the same effector molecules downstream of MRP14 can have bilateral effects on pathology during leishmaniasis, i.e., protectively in CL and detrimentally in VL. Quantitative PCR analyses demonstrated that MRP14 acts as an enhancer for NO2 and IFN-γ mRNA expressions in the spleen of L. donovani-infected mice (Fig 5). It is well known that these two molecules contribute to control of CL [45,46], whereas they may promote anemia during VL. We previously reported that infected macrophages in the spleen engulf erythrocytes during VL and proposed that the phenomenon, called hemophagocytosis, is one of the possible causes of anemia during VL [43]. Hemophagocytosis results from hyper-activation of macrophages by

Fig 5. MRP14-dependent expressions of IFN-γ and NO2 genes in the spleen of L. donovani-infected mice. The spleens were harvested from naive or L. donovani-infected WT (n = 4 or 5) and MRP14KO mice (n = 4 or 5) and total RNA was purified from the tissues. Expression levels of MRP8, MRP14, Tnfα, NO2 and IFN-γ mRNA in the organs were measured by quantitative PCR. Mean and SD of each group are shown. ns, not significant, *P < 0.05 by Mann-
Whitney test. These are a representative of three independent experiments with similar results.

https://doi.org/10.1371/journal.pntd.0008020.g005
many reasons. In the case of VL, most of the hemophagocytes in the spleen were multinucleated giant cells (MGC) heavily infected with *L. donovani* [43]. IFN-γ has a crucial role in MGC formation [47]. Interestingly, Zoller *et al.* reported that systemic exposure to physiologically relevant levels of IFN-γ is sufficient to cause hemophagocytosis [48]. In addition, IFN-γ-deficient mice do not exhibit hemophagocytosis and anemia during *Trypanosoma brucei* infection [49]. These reports suggest that MRP14 contribute to development of anemia by inducing IFN-γ which results in up-regulated hemophagocytosis, at least in the status that infection is not well controlled. But, the major source of IFN-γ during *L. donovani* infection may not be T cells since antigen-specific induction of IFN-γ production was not observed in splenocytes from the infected MRP14KO mice (Fig 4) NK cells and ILC1 cells are known innate immune cells as a source of IFN-γ [50]. MRP14 can activate NK cells and support IFN-γ production [51,52], suggesting the molecule affects immune responses through direct activation of innate immunity rather than manipulating acquired immunity.

In conclusion, we have demonstrated the different pathological roles of MRP14 during experimental CL and VL. To our knowledge, this is the first report addressing the roles of MRP14 in *L. donovani* infection. Although MRP14 is associated with a wide range of inflammatory diseases, the functions remain elusive. Our study that the functions vary even between *L. major* and *L. donovani* infection may prove the complexity of MRP14, but at the same time support understanding of the mechanisms behind the complexity. Nonetheless, studies using MRP14-KO mice are insufficient to elucidate the complex roles of MRP14 in infectious diseases, and further studies using MRP14-reporter mice, MRP14-conditional KO mice, MRP14 inhibitors and anti-MRP14 antibody for flow cytometry are definitely required. Development of such the research tools will lead to understanding of multifunctional roles of MRP14.

**Supporting information**

S1 Table. Primer list for quantitative PCR analyses.

(DOCX)

**Acknowledgments**

We thank Mr. Kai Sato and Ms. Jing Hong for their technical supports.

**Author Contributions**

Conceptualization: Kanna Ishizuka, Haruka Mizobuchi, Yasuyuki Goto.

Data curation: Kanna Ishizuka, Yasuyuki Goto.

Formal analysis: Kanna Ishizuka, Yasuyuki Goto.

Funding acquisition: Wataru Fujii, Haruka Mizobuchi, Ayako Morimoto, Yasuyuki Goto.

Investigation: Kanna Ishizuka, Natsuho Azuma, Ayako Morimoto, Yasuyuki Goto.

Methodology: Kanna Ishizuka, Wataru Fujii, Haruka Mizobuchi, Ayako Morimoto, Chizu Sanjoba, Yoshitsugu Matsumoto, Yasuyuki Goto.

Project administration: Yasuyuki Goto.

Resources: Wataru Fujii, Haruka Mizobuchi, Ayako Morimoto, Chizu Sanjoba, Yoshitsugu Matsumoto, Yasuyuki Goto.

Supervision: Yasuyuki Goto.

Validation: Yasuyuki Goto.
Visualization: Yasuyuki Goto.

Writing – original draft: Kanna Ishizuka.

Writing – review & editing: Yasuyuki Goto.

References

1. Edgeworth J, Gorman M, Bennett R, Freemont P, Hogg N. Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J Biol Chem. 1991; 266: 7706–7713. PMID: 2019594

2. Hunter MJ, Chazin WJ. High level expression and dimer characterization of the S100 EF-hand proteins, migration inhibitory factor-related proteins 8 and 14. J Biol Chem. 1998; 273: 12427–12435. https://doi.org/10.1074/jbc.273.20.12427 PMID: 9575199

3. Kilgman D, Hilt DC. The S100 protein family. Trends Biochem Sci. 1988; https://doi.org/10.1016/0968-0004(88)90218-6

4. Odink K, Cerletti N, Brüggen J, Clerc RG, Tarcsay L, Zwasdlo G, et al. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature. 1987; 330: 80–82. https://doi.org/10.1038/330080a0 PMID: 3313057

5. Roth J, Vogl T, Sorg C, Sunderko C. Phagocyte-speci c S100 proteins: a novel group of proin ammatory molecules. Trends Immunol. 2003; 24: 155–158. https://doi.org/10.1016/s1471-4906(03)00062-0 PMID: 12697438

6. Lagasse E, Weissman IL. Mouse MRP8 and MRP14, two intracellular calcium-binding proteins associated with the development of the myeloid lineage. Blood. 1992; 79: 1907–1915. PMID: 1373330

7. Gebhardt C, Németh J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol. 2006; 72: 1622–1631. https://doi.org/10.1016/j.bcp.2006.05.017 PMID: 16846592

8. Ehren JM, Sundekerter C, Voel D, Vogt T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009; 86: 557–566. https://doi.org/10.1189/jlb.1008647 PMID: 19451397

9. Vogl T, Garibyan AL, Morozova-Roche LA. Pro-inflammatory S100A8 and S100A9 proteins: Self-assembly into multifunctional native and amyloid complexes. Int J Mol Sci. 2012; 13: 2893–2917. https://doi.org/10.3390/ijms13032893 PMID: 22489132

10. Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin- dependent pathway. J Biol Chem. 1997; 272: 9496–9502. https://doi.org/10.1074/jbc.272.14.9496 PMID: 9083090

11. Mizobuchi H, Fujiw M, Isokawa S, Ishizuka K, Wang Y, Watanabe S, et al. Exacerbation of hepatic injury during rodent malaria by myeloid-related protein 14. PLoS One. 2018; 13: e0199111. https://doi.org/10.1371/journal.pone.0199111 PMID: 29902248

12. Riva M, Källberg E, Björk P, Hancz D, Vogt T, Roth J, et al. Induction of nuclear factor-κB responses by the S100A9 protein is Toll-like receptor-4-dependent. Immunology. 2012; 137: 172–182. https://doi.org/10.1111/j.1365-2567.2012.03619.x PMID: 22804476

13. Boyd JH, Kan B, Roberts H, Wang Y, Walley KR. S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res. 2008; https://doi.org/10.1161/CIRCRESAHA.107.167544 PMID: 18403730

14. Ghavami S, Rashedi I, Dattilo BM, Eshraghi M, Chazin WJ, Hashemi M, et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol. 2008; https://doi.org/10.1189/jlb.0607397 PMID: 18339893

15. Tsai SY, Segovia JA, Chang TH, Morris IR, Berton MT, Tessier PA, et al. DAMP Molecule S100A9 Acts as a Molecular Pattern to Enhance Inflammation during Influenza A Virus Infection: Role of DD21-TRIF-TLR4-MyD88 Pathway. PLoS Pathog. 2014;10. https://doi.org/10.1371/journal.ppat.1003848 PMID: 24391503

16. Wu R, Duan L, Cui F, Cao J, Xiang Y, Tang Y, et al. S100A9 promotes human hepatocellular carcinoma cell growth and invasion through RAGE-mediated ERK1/2 and p38 MAPK pathways. Exp Cell Res. 2015; https://doi.org/10.1016/j.yexcr.2015.04.008 PMID: 25907296

17. Chen B, Miller AL, Rebela M, Brewah Y, Rowe DC, Clarke L, et al. S100A9 Induced inflammatory responses are mediated by distinct damage associated molecular patterns (DAMP) receptors in vitro and in vivo. PLoS One. 2015;10. https://doi.org/10.1371/journal.pone.0115828 PMID: 25706559
18. Frosch M, Vogl T, Seeliger S, Wulffraat N, Kuis W, Viemann D, et al. Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2003; 48: 2622–2626. https://doi.org/10.1002/art.11177 PMID: 13130482

19. Altvegg LA, Neidhart M, Hersberger M, Müller S, Eberli FR, Corti R, et al. Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: A novel, easy, and sensitive marker of acute coronary syndromes. Eur Heart J. 2007; 28: 941–948. https://doi.org/10.1093/eurheartj/ehm078 PMID: 17387139

20. Benoît S, Toksoy A, Ahlmann M, Schmidt M, Sunderkötter C, Foell D, et al. Elevated serum levels of calcium-binding S100 proteins A8 and A9 reflect disease activity and abnormal differentiation of keratinocytes in psoriasis. Br J Dermatol. 2006; 155: 62–66. https://doi.org/10.1111/j.1365-2133.2006.07198.x PMID: 16792753

21. Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkötter C, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000; 43: 628–637. https://doi.org/10.1002/1529-0131(200003)43:3<628::AID-ANR20>3.0.CO;2-X PMID: 10729757

22. Van Lent PLEMEM, Grevers L, Blom AB, Sloetjes A, Mort JS, Vogl T, et al. Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. Ann Rheum Dis. 2008; 67: 1750–1758. https://doi.org/10.1136/ard.2007.077800 PMID: 18055478

23. Croce K, Gao H, Wang Y, Mooroka T, Sakuma M, Shi C, et al. Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation. 2009; 120: 427–436. https://doi.org/10.1161/CIRCULATIONAHA.108.814582 PMID: 19620505

24. Mizobuchi H, Yamakoshi S, Omachi S, Osada Y, Sanjoba C, Goto Y, et al. The accumulation of macrophages expressing myeloid-related protein 8 (MRP8) and MRP14 in the spleen of BALB/c mice during infection with Plasmodium berghei. Exp Parasitol. 2014; 138: 1–8. https://doi.org/10.1016/j.exppara.2014.01.003 PMID: 24440297

25. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet. 2005. https://doi.org/10.1016/S0140-6736(05)67629–5

26. Lukes J, Mauricio IL, Schonian G, Dujaardin J-C, Soteriadou K, Dedet J-P, et al. Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy. Proc Natl Acad Sci. 2007; https://doi.org/10.1073/pnas.0703678104 PMID: 17517634

27. Goto Y, Sanjoba C, Arakaki N, Okamoto M, Saeki K, Onodera T, et al. Accumulation of macrophages expressing MRP8 and MRP14 in skin lesions during Leishmania major infection in BALB/c and RAG-2 knockout mice. Parasitol Int. 2007; https://doi.org/10.1016/j pari.2007.02.007 PMID: 17409015

28. Conteras I, Shio MT, Cesaro A, Tessier PA, Olivier M. Impact of Neutrophil-Secreted Myeloid Related Proteins 8 and 14 (MRP 8/14) on Leishmania Progression. PLoS Negl Trop Dis. 2013; https://doi.org/10.1371/journal.pntd.0002461 PMID: 24086877

29. Mizobuchi H, Fuji W, Ishizuka K, Wang Y, Watanabe S, Sanjoba C, et al. MRP14 is dispensable for LPS-induced shock in BALB/c mice. Immunol Lett. Elsevier; 2018; 194: 13–20. https://doi.org/10.1016/j.imlet.2017.12.003 PMID: 29253495

30. Fuji W, Onuma A, Sugira K, Naito K. Efficient generation of genome-modified mice via offset-nicking by CRISPR/Cas system. Biochem Biophys Res Commun. Elsevier Inc.; 2014; 445: 791–794. https://doi.org/10.1016/j.bbr.2014.01.141 PMID: 24491566

31. Pandey K, Yanagi T, Pandey BD, Mallik AK, Sherchand JB, Kanbara H. Characterization of Leishmania isolates from Nepalese patients with visceral leishmaniasis. Parasitol Res. 2007; https://doi.org/10.1007/s00436-007-0464-4 PMID: 17310397

32. Belkaid Y, Mendez S, Lira R, Kadambi N, Milon G, Sacks D. A natural model of Leishmania major infection reveals a prolonged “silent” phase of parasite amplification in the skin before the onset of lesion formation and immunity. J Immunol. 2000;

33. Belkaid Y, Kamhawi S, Modì G, Valenzuela J, Noben-Trauth N, Rowton E, et al. Development of a natural model of cutaneous leishmaniasis: Powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J Exp Med. 1998; https://doi.org/10.1084/jem.188.10.1941 PMID: 9815271

34. Iborra S, Carrión J, Anderson C, Alonso C, Sacks D, Soto M. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice. Infect Immun. 2005; https://doi.org/10.1128/IAI.73.9.5842–5852.2005

35. Anderson CF, Mendez S, Sacks DL. Nonhealing infection despite Th1 polarization produced by a strain of Leishmania major in C57BL/6 mice. J Immunol. 2005;
36. Huff CG, Nolf LO, Porter RJ, Read CP, Richards AG, Riker AJ, et al. An Approach toward a Course in the Principles of Parasitism. J Parasitol. 2006; https://doi.org/10.2307/3274825

37. Jonczyk MS, Simon M, Kumar S, Fernandes VE, Sylvius N, Mallon AM, et al. Genetic factors regulating lung vasculature and immune cell functions associate with resistance to pneumococcal infection. PLoS One. 2014; https://doi.org/10.1371/journal.pone.0089831 PMID: 24594938

38. Wang SS, Song R, Wang Z, Jing Z, Wang SS, Ma J. S100A8/A9 in inflammation. Frontiers in Immunology. 2018. https://doi.org/10.3389/fimmu.2018.01298 PMID: 29942307

39. Steinbrink K, Schönlaub F, Rescher U, Henseleit U, Vogel C, et al. Ineffective elimination of leishmaniasis major by inflammatory (MRP14-positive) subtype of monocytic cells. Immunobiology. 2000; https://doi.org/10.1016/S0171-2985(00)80103-5

40. Viemann D, Strey A, Janning A, Jurk K, Klimmek K, Vogl T, et al. Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood. 2005; https://doi.org/10.1182/blood-2004-07-2520 PMID: 15598812

41. Méndez S, Gurunathan S, Kamhawi S, Belkaid Y, Moga MA, Skeiky YAW, et al. The Potency and Durability of DNA- and Protein-Based Vaccines Against Leishmaniasis major Evaluated Using Low-Dose, Intradermal Challenge. J Immunol. 2001; https://doi.org/10.4049/jimmunol.166.8.5122 PMID: 11290794

42. Muraille E, De Trez C, Pajak B, Torrentera FA, De Baetselier P, Leo O, et al. Amastigote load and cell surface phenotype of infected cells from lesions and lymph nodes of susceptible and resistant mice infected with Leishmaniasis major. Infect Immun. 2003; https://doi.org/10.1128/IAI.71.5.2704–2715.2003

43. Morimoto A, Omachi S, Osada Y, Chambers JK, Uchida K, Sanjoba C, et al. Hemophagocytosis in Experimental Visceral Leishmaniasis by Leishmania donovani. PLoS Negl Trop Dis. 2016; https://doi.org/10.1371/journal.pntd.0004505 PMID: 26942577

44. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 2008; https://doi.org/10.1088/1742-5114/1/6/5122 PMID: 20403472

45. Wang ZE. CD4+ effector cells default to the Th2 pathway in interferon gamma-deficient mice infected with Leishmaniasis major. J Exp Med. 2004; https://doi.org/10.1084/jem.179.4.1367 PMID: 7908325

46. Wei XQ, Charles IG, Smith A, Ure J, Feng GJ, Huang FP, et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature. 1995. https://doi.org/10.1038/375408a0 PMID: 7539113

47. Möst J, Neumayer HP, Dierich MP. Cytokine-induced generation of multinucleated giant cells in vitro requires interferon-y and expression of LFA-1. Eur J Immunol. 1990; https://doi.org/10.1002/eji.1830200807 PMID: 1976520

48. Zoller EE, Lykens JE, Terrell CE, Aliberti J, Filipovich AH, Henson PM, et al. Hemophagocytosis causes a consumptive anemia of inflammation. J Exp Med. 2011; https://doi.org/10.1084/jem.20102538 PMID: 21624938

49. Cronie J, De Trez C, Stijlemans B, Keirse J, Kauffmann F, Barkhuizen M, et al. NK-, NKT- and CD8- Derived IFN\gamma Drives Myeloid Cell Activation and Erythropagocytosis, Resulting in Trypanosomosis-Associated Acute Anemia. PLoS Pathog. 2015; https://doi.org/10.1371/journal.ppat.1004964 PMID: 26070118

50. Ivanova DL, Denton SL, Fettel KD, Sondgroth KS, Gutierrez JM, Bangoura B, et al. Innate lymphoid cells in protection, pathology, and adaptive immunity during apicomplexan infection. Frontiers in Immunology. 2019. https://doi.org/10.3389/fimmu.2019.00196 PMID: 30873151

51. Narumi K, Miyakawa R, Ueda R, Hashimoto H, Yamamoto Y, Yoshida T, et al. Proinflammatory Proteins S100A8/S100A9 Activate NK Cells via Interaction with RAGE. J Immunol. 2015; https://doi.org/10.4049/jimmunol.1402301 PMID: 25911757

52. Moreno-Nieves UY, Didier C, Lévy Y, Barré-Sinoussi F, Scott-Algara D. S100A9 tetramers, which are ligands of CD85j, increase the ability of MVA HIV-primed NK cells to control HIV infection. Front Immunol. 2015; https://doi.org/10.3389/fimmu.2015.00478 PMID: 26441983